InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
0
T+90 hit rate
40%
T+90 mean return
-16.6%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Ricciardi Lisa, Chairman & CEO. Insider active across 1 company, notably Cognition Therapeutics INC. Cumulatively, 13 disclosures have been published. Split: 5 buys · 0 sell. Total volume traded: €191k. Activity tracked since 13 October 2021. The latest transaction was disclosed on 16 April 2026 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Ricciardi Lisa
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations13 total
9,175 shares@ US$1.100.0093% mcap2.2% of flowCommon StockSEC:0001104659-26-045502:0
Canonical exit: 15 Jul 2026 (T+90)
5,850 shares@ US$1.122.1% of flowCommon StockSEC:0001104659-26-017070:0
800,000 shares0Common StockSEC:0001104659-26-011075:0
75,000 shares0Common StockSEC:0001104659-25-123727:0
75,000 shares0Common StockSEC:0001062993-25-013356:0
6,619 shares@ US$0.59011.0% of flowCommon StockSEC:0001062993-25-002705:0
38,851 shares@ US$0.77227.7% of flowCommon StockSEC:0001062993-25-001617:0
Canonical exit: 1 May 2025 (T+90)
5,700 shares@ US$1.752.4% of flowCommon StockSEC:0001062993-24-006429:0
Canonical exit: 12 Jun 2024 (T+90)
75,000 shares0Common StockSEC:0001062993-24-003644:0
27,828 shares@ US$2.2915.7% of flowCommon StockSEC:0001062993-24-002774:0
213,973 shares0Common StockSEC:0000899243-23-004182:0
12,000 shares@ US$1.304.0% of flowCommon StockSEC:0001062993-22-022243:0
Canonical exit: 13 Feb 2023 (T+90)
12,500 shares@ US$12.0050.0% of flowCommon StockSEC:0001104659-21-126362:0
Canonical exit: 11 Jan 2022 (T+90)
13 of 13 declarations
About Ricciardi Lisa
Ricciardi Lisa is Président-Directeur Général and a declarant linked to Cognition Therapeutics INC, where she is CEO & President. The 13 filings on record, all included in the sampled set, cover transactions from 2021-10-14 to 2026-04-20, with EUR 190957 of purchases and EUR 0 of sales, and the modal transaction nature is Acquisition.
